Star Scientific Reports First Peer-Reviewed Article on Anatabine and Alzheimer’s Disease by Roskamp Institute

By Star Scientific Inc., PRNE
Monday, October 3, 2011

GLEN ALLEN, Virginia, October 4, 2011 -

Star Scientific, Inc. (Nasdaq: CIGX) reports today the publication of the first peer-reviewed article on the in-vitro and in-vivo activity of anatabine in Alzheimer’s Disease. The article is authored by scientists at the Roskamp Institute and is electronically published in the European Journal of Pharmacology (2011 Sept 19).  It states that anatabine lowers Alzheimer’s A-beta production in-vitro and in-vivo.  

(Logo: )

In the article the authors describe the accumulation of an abnormal substance, called A-beta, the substance that leads to amyloid formation and damage to brain tissue. They studied the formation of A-beta and showed how anatabine lowers levels of two forms of A-beta (1-40 and 1-42) in a dose-dependent manner, possibly by preventing or reducing formation from the precursor protein. After showing the activity in the test tube, the researchers went on to show that when anatabine is given to mice vulnerable to accumulation of amyloid, treatment with anatabine lowers brain levels of both A-beta (1-40) and A-beta (1-42), postulated to be due to effects on NFKB activation. Michael Mullan, MD, Ph.D.,  Roskamp Institute co-director and one of the article’s authors, commented, “This paper demonstrates anatabine’s potential as an anti-inflammatory agent and shows it may have broad applications including for disorders like Alzheimer’s Disease.”

Anatabine citrate is one of the active ingredients in Anatabloc™, a dietary supplement developed by Star Scientific’s subsidiary, Rock Creek Pharmaceuticals.  Anatabloc™, which entered the market on August 30,  is designed to provide anti-inflammatory support (  Curtis Wright, MD, MPH, Senior Vice President of Rock Creek Pharmaceuticals, expressed his opinion of the Roskamp findings. “While we were aware that Roskamp was conducting studies of the effects of dietary supplementation with anatabine in Alzheimer’s Disease, it is gratifying that external peer review validated the work they have done. The research confirms that this natural plant compound shows an interesting regulatory effect on brain immune responses. It is one thing to believe your own results; it is quite another to have them accepted by your peers in the scientific community.”  Anatabine for the Roskamp research was provided through Rock Creek Pharmaceuticals.

Ongoing human clinical studies of anatabine citrate, and the commercial product Anatabloc™, are examining the potential role of nutritional supplementation in regulating low-level inflammation controlled by the NFκB system.

Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “continues,” “likely,” “may,” “opportunity,” “potential,” “projects,” “will,” “expects,” “plans,” “intends” and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, without limitation, the challenges inherent in new product development initiatives through Star Tobacco and Rock Creek, the uncertainties inherent in the progress of scientific research, our ability to raise additional capital in the future that is necessary to maintain our business, potential disputes concerning our intellectual property, risks associated with litigation regarding such intellectual property, uncertainties associated with the development, testing and regulatory approvals of our low-TSNA tobacco,  related tobacco  products and pharmaceutical and nutraceutical products , market acceptance of our new smokeless tobacco products and nutraceutical and pharmaceutical products, competition from companies with greater resources than us,  our dependence on key employees and on our prior strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with R.J. Reynolds Tobacco Company, Inc.  Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. See additional discussion under “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 16, 2011, and other factors detailed from time to time in the Company’s other filings with the SEC, available at All information in this release is current as of this date, and the Company undertakes no obligation to update or advise upon any such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

About Star Scientific Star Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins, principally through the utilization of the innovative StarCured® tobacco curing technology. Its subsidiary, Rock Creek Pharmaceuticals, Inc., is involved in the development of nutraceuticals as well as products to address neurological and mood disorders. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, D.C.  Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA. See Star’s website at:

Sara Troy Machir
Vice President,  Communications & Investor Relations


will not be displayed